Clinical Trial Update: A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients [Phase 2]

View source ↗

Summary

A Phase 2, single-center, double-blind trial evaluating MEM 3454 for effects on P50 sensory gating and mismatch negativity in schizophrenia patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• MEM 3454

Snippet

Sponsor: Memory Pharmaceuticals | Conditions: Schizophrenia | Phase 2 | Status: UNKNOWN